A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 19, 2018

Primary Completion Date

October 5, 2018

Study Completion Date

October 5, 2018

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

SAR425899

"Pharmaceutical form: Solution~Route of administration: Subcutaneous"

Trial Locations (3)

Investigational Site Number 8400003, Knoxville

Investigational Site Number 8400002, Saint Paul

Investigational Site Number 8400001, Austin